Jack T Stapleton1, Nancy Wagner2, Rebecca Tuetken2, Abbie R Bellamy3, Heather Hill3, Sonnie Kim4, Patricia L Winokur2. 1. Department of Internal Medicine and Iowa City Veterans Affairs Medical Center, Iowa City, IA 52242, United States; Microbiology and Immunology, The University of Iowa, Iowa City Veterans Affairs Medical Center, Iowa City, IA 52242, United States; Research and Medical Services, Iowa City Veterans Affairs Medical Center, Iowa City, IA 52242, United States. Electronic address: jack-stapleton@uiowa.edu. 2. Department of Internal Medicine and Iowa City Veterans Affairs Medical Center, Iowa City, IA 52242, United States. 3. The Emmes Corporation, Rockville, MD, United States. 4. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States.
Abstract
INTRODUCTION:Subjects with rheumatoid arthritis (RA) receivingtumor necrosis factor-inhibiting (TNFi) therapies are at risk for severe influenza, and may respond less well to influenza vaccine. We examined the safety and immunogenicity of high dose influenza vaccine (HD) compared to standard dose vaccine (SD) in participants with RA receiving stable TNFi. METHODS: A randomized, double-blinded, Phase II study was conducted in adults with RA receiving TNFi, and healthy, gender and age-matched control subjects. Participants were immunized with HD (Sanofi Pasteur Fluzone High Dose [60 mcg× 3 strains]) or SD (Sanofi Pasteur Fluzone® [15 mcg × 3 strains]) intramuscularly (IM). A self-administered memory aid recorded temperature and systemic and local adverse events (AEs) for 8 days, and safety was evaluated and serum obtained to measure HAI activity on days 7, 21 and 180 days following vaccination. RESULTS: A greater proportion of RA subjects who received HD seroconverted at day 21 compared to SD, although this was not statistically significant. GMT antibody responses in RA subjects who received HD compared to SD were greater for all strains on day 21, and this was significant for H1N1. Seroconversion rates and GMT values were not different between RA subjects and control subjects. There were no safety concerns for HD or SD in RA subjects, and RA-related symptoms did not differ between SD and HD recipients by a RA-symptom questionnaire (RAPID 3). CONCLUSIONS:TNF-inhibitor therapy in people with RA did not appear to influence the immunogenicity of either SD or HD. Influenza seroconversion and GMT values were higher among RA subjects receiving HD compared to SD; however, differences were small and a larger study is needed to validate these findings. Given the apparent risk of increased influenza-related morbidity and mortality among immune compromised subjects, the higher GMT values generated by HD may be beneficial. Published by Elsevier Ltd.
RCT Entities:
INTRODUCTION: Subjects with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibiting (TNFi) therapies are at risk for severe influenza, and may respond less well to influenza vaccine. We examined the safety and immunogenicity of high dose influenza vaccine (HD) compared to standard dose vaccine (SD) in participants with RA receiving stable TNFi. METHODS: A randomized, double-blinded, Phase II study was conducted in adults with RA receiving TNFi, and healthy, gender and age-matched control subjects. Participants were immunized with HD (Sanofi Pasteur Fluzone High Dose [60 mcg × 3 strains]) or SD (Sanofi Pasteur Fluzone® [15 mcg × 3 strains]) intramuscularly (IM). A self-administered memory aid recorded temperature and systemic and local adverse events (AEs) for 8 days, and safety was evaluated and serum obtained to measure HAI activity on days 7, 21 and 180 days following vaccination. RESULTS: A greater proportion of RA subjects who received HD seroconverted at day 21 compared to SD, although this was not statistically significant. GMT antibody responses in RA subjects who received HD compared to SD were greater for all strains on day 21, and this was significant for H1N1. Seroconversion rates and GMT values were not different between RA subjects and control subjects. There were no safety concerns for HD or SD in RA subjects, and RA-related symptoms did not differ between SD and HD recipients by a RA-symptom questionnaire (RAPID 3). CONCLUSIONS:TNF-inhibitor therapy in people with RA did not appear to influence the immunogenicity of either SD or HD. Influenza seroconversion and GMT values were higher among RA subjects receiving HD compared to SD; however, differences were small and a larger study is needed to validate these findings. Given the apparent risk of increased influenza-related morbidity and mortality among immune compromised subjects, the higher GMT values generated by HD may be beneficial. Published by Elsevier Ltd.
Authors: Stefan Gravenstein; H Edward Davidson; Monica Taljaard; Jessica Ogarek; Pedro Gozalo; Lisa Han; Vincent Mor Journal: Lancet Respir Med Date: 2017-07-20 Impact factor: 30.700
Authors: A M Palache; W E Beyer; M J Sprenger; N Masurel; S de Jonge; A Vardy; B Charpentier; J Noury; W C van Beek; R J Borst Journal: Vaccine Date: 1993 Impact factor: 3.641
Authors: Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot Journal: N Engl J Med Date: 2014-08-14 Impact factor: 91.245
Authors: Ori Elkayam; Amir Bashkin; Michal Mandelboim; Irena Litinsky; Doron Comaheshter; David Levartovsky; Ella Mendelson; Irena Wigler; Dan Caspi; Daphna Paran Journal: Semin Arthritis Rheum Date: 2009-02-26 Impact factor: 5.532
Authors: Michel Chevallard; Antonella Adinolfi; Laura Belloli; Cinzia Casu; Maria Di Cicco; Chiara Destefani; Bartolomeo Di Rosa; Maria Giovanna Gentile; Davide Antonio Filippini; Angela Luisi; Marina Muscarà; Emanuela Schito; Nicola Ughi; Elisa Verduci; Emanuela Marta Vincenti; Laura Zoppini; Oscar Massimiliano Epis Journal: Clin Rheumatol Date: 2022-10-07 Impact factor: 3.650